Select therapeutic use:
Indications for BICILLIN C-R:
Susceptible moderately severe infections including respiratory, skin and soft tissue, erysipelas, scarlet fever, otitis media.
Adults and Children:
C-R: Give by deep IM inj (buttock or, in young children, may give in anterolateral thigh). Group A strep: <30lbs: 600,000 units; 30–60lbs: 900,000–1.2 million units; >60lbs: 2.4 million units; all as single dose (may split injections) or may give one-half total dose on day 1 and one-half on day 3. Pneumococcal (except meningitis) children: 600,000 units; adults 1.2 million units; give every 2–3 days until afebrile for 48 hrs.
Avoid intraarterial, intravascular, and intraneural inj.
Not for IV use. Do not admix with other IV solutions. Reports of inadvertent IV administration has been associated with cardiorespiratory arrest and death.
Not for IV use. Cephalosporin, imipenem, or other allergy: not recommended. Asthma. Monitor renal and hematopoietic function in prolonged use. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. May cause false (+) glucose test with Clinitest.
Rash, drug fever, serum sickness, anaphylaxis, blood dyscrasias, neuropathy, nephropathy, inj site reactions.
C–R Tubex 600,000 units/mL (1mL, 2mL)—10 (w. 1 inch or 1.25 inch needles); C–R disposable syringe 600,000 units/mL (4mL)—10 (w. 2 inch needles); C–R 900/300 Tubex 1.2 million units/syringe (2mL)—10 (w. 1 inch or 1.25 inch needles)